硼替佐米联合地塞米松治疗老年多发性骨髓瘤的临床效果及对血小板生成素和免疫细胞水平的影响

Abstract
Figure/Table
References (17)
Related Citation (15)

Download: PDF (0 KB) HTML (41 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the clinical effect of Bortezomib combined with Dexamethasone in the treatment of elderly multiple myeloma and the influence on the levels of thrombopoietin and immune cells.Methods A total of 40 elderly patients with multiple myeloma admitted to Shangrao Municipal Hospital of Jiangxi Province from January 2015 to October 2020 were selected as the research objects and divided into the control group(20 cases)and the observation group(20 cases)according to the random drawing lots method.The control group was treated with Vincristine,Dexamethasone combined with Epirubicin,and the observation group was treated with Bortezomib combined with Dexamethasone.The therapeutic effects the levels of immunosuppressive factors(interleukin-6[IL-6]and interleukin-17[IL-17]),immune cells(CD3+CD4+,CD3+CD8+,CD3+CD4+/CD3+CD8+),thrombopoietin(TPO)and transforming growth factor-β(TGF-β)before and after treatment were compared between the two groups.Results After treatment,the total effective rate of the observation group was higher than that of the control group,the difference was statistically significant(P<0.05).The IL-6 and IL-17 of the observation group were lower than those of the control group,the differences were statistically significant(P<0.05).The CD3+CD4+,CD3+CD4+/CD3+CD8+ of the observation group were higher than those of the control group,the CD3+CD8+ of the observation group was lower than that of the control group,the differences were statistically significant(P<0.05).The TPO and TGF-β in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).Conclusion The clinical effect of Bortezomib combined with Dexamethasone in the treatment of elderly multiple myeloma is significant,which can not only improve the level of immunosuppressive factors,but also improve the level of immune cells,which is suitable for clinical implementation and development.

Key words： Senile multiple myeloma Clinical efficacy;Thrombopoietin Interleukin-6 Influence

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	RUI Ming-zhong
	WANG Zi-yan
	LU Xi

Cite this article:

RUI Ming-zhong,WANG Zi-yan,LU Xi. Clinical effect of Bortezomib combined with Dexamethasone in the treatment of elderly multiple myeloma and the influence on the levels of thrombopoietin and immune cells[J]. 中国当代医药, 2021, 28(22): 55-58.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I22/55

[1]	李晓晗，薛磊，徐慧，等.树突状细胞介导的肿瘤相关抗原特异性T 淋巴细胞治疗多发性骨髓瘤和非霍奇金淋巴瘤的临床研究[J].中国实验血液学杂志，2020，28（5）：1750-1756.
[2]	张春燕，胡致平，邓姝，等.多发性骨髓瘤从痰瘀论治[J].中国现代医生，2020，58（11）：156-158，162.
[3]	黄刚，廖建军，黄继贤，等.硼替佐米+环磷酰胺+地塞米松治疗多发性骨髓瘤的临床疗效及安全性探讨[J].中国现代药物应用，2020，14（10）：159-160.
[4]	徐璐，陈峙霖，胡敏，等.临床特征、实验室指标和治疗方案对多发性骨髓瘤患者预后影响的研究[J].中国实验血液学杂志，2019，27（4）：1166-1172.
[5]	张媛媛.VTD 治疗多发性骨髓瘤的临床疗效观察[J].医学理论与实践，2020，33（20）：3407-3408.
[6]	黄亚丽，杨丽萍，谢治军，等.硼替佐米为主化疗方案治疗多发性骨髓瘤患者临床疗效及生存影响因素分析[J].河北医学，2020，26（7）：1186-1192.
[7]	田杏.多柔比星脂质体联合低剂量沙利度胺治疗多发性骨髓瘤的临床分析[J].世界最新医学信息文摘（连续型电子期刊），2020，20（12）：8，278.
[8]	肖汇颖，胡冬菊，王永敏，等.活血逐瘀方联合化疗治疗多发性骨髓瘤临床疗效及对机体免疫功能的影响[J].中华中医药学刊，2020，38（6）：160-164.
[9]	祁岳坤，徐开林.抗BCMA 联合抗CD19CAR-T 细胞治疗复发/难治多发性骨髓瘤：单臂Ⅱ期临床试验[J].临床血液学杂志，2020，33（7）：460-463.
[10]	吕乃武，王红梅，刘福庆，等.硼替佐米联合地塞米松治疗多发性骨髓瘤患者的临床疗效观察[J].国际医药卫生导报，2020，26（1）：108-109.
[11]	许晓东，曹俊杰，庄贤栩，等.伊沙佐米治疗难治复发多发性骨髓瘤临床疗效及相关毒副反应研究[J].临床血液学杂志，2020，33（3）：205-207.
[12]	吴桂香，夏维林，杨克，等.硼替佐米联合来那度胺及地塞米松治疗多发性骨髓瘤临床疗效观察[J].汕头大学医学院学报，2020，33（1）：31-33.
[13]	周西，刘启榆，王忠，等.经皮球囊扩张椎体后凸成形术治疗多发性骨髓瘤导致椎体骨折的临床效果[J].中外医学研究，2020，18（5）：14-16.
[14]	宫敬智，杨雷，白培清，等.西达本胺联合雷利度胺和地塞米松治疗多发性骨髓瘤的临床研究[J].解放军医药杂志，2020，32（2）：36-39.
[15]	高阳，崔秀娟，赵春宝，等.低剂量沙利度胺联合地塞米松治疗难治性多发性骨髓瘤的临床观察[J].临床医药文献电子杂志，2020，7（2）：157.
[16]	汪勇，汪琼，吴玉玲，等.以硼替佐米为主的联合化疗方案治疗多发性骨髓瘤临床观察[J].白血病·淋巴瘤，2020，29（5）：284-287.
[17]	钟龙，姚福生.改良VTD 方案治疗老年多发性骨髓瘤的临床疗效及对血清TPO 和IL-6 水平的影响[J].医学综述，2020，26（20）：4147-4152.